NMRA Share Price Performance
US$2.19
1.53 (231.82%)
75.4% undervalued intrinsic discount
US$8.91
Fair Value
Price US$2.19
AnalystConsensusTarget US$8.91
AnalystHighTarget US$17.85
Fair ValueUS$8.91
Share Pricen/a
Neumora Therapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
NMRA Community Narratives
AN
Fair Value US$8.91 75.4% undervalued intrinsic discount
CNS And Obesity Pipeline Will Create Long Term Value As Late Stage Data Emerges
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$17.85 87.7% undervalued intrinsic discount
Multiple Late Stage Brain Disease Programs Will Drive Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Multiple Late Stage Brain Disease Programs Will Drive Long Term Upside Potential
Catalysts About Neumora Therapeutics Neumora Therapeutics develops brain penetrant medicines targeting novel mechanisms for psychiatric, neurologic and metabolic diseases. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$17.85
87.7% undervalued intrinsic discount
Fair Value
Profit Margin
19.89%
Future PE
171.54x
Price in 2029
US$0
CNS And Obesity Pipeline Will Create Long Term Value As Late Stage Data Emerges
Catalysts About Neumora Therapeutics Neumora Therapeutics focuses on developing brain penetrant medicines for neuropsychiatric, neurodegenerative, and metabolic diseases. What are the underlying business or industry changes driving this perspective?Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$8.91
75.4% undervalued intrinsic discount
Fair Value
Profit Margin
19.89%
Future PE
191.44x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Multiple Late Stage Brain Disease Programs Will Drive Long Term Upside Potential
Fair Value: US$17.85 87.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CNS And Obesity Pipeline Will Create Long Term Value As Late Stage Data Emerges
Fair Value: US$8.91 75.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Neumora Therapeutics, Inc. Key Details
About NMRA
- Founded
- 2019
- Employees
- 96
- CEO
- WebsiteView website
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease. In addition, the company’s preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Recent NMRA News & Updates
